Komori
ASKA Pharmaceutical Holdings (4886) · FactAdvanced

Revenue Growth and Improved Operating Margin in FY2022

First written in FY2023. 3 of 5 entries say "Advanced", first in FY2024. Latest entry: FY2026.

5entries
4years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024WorsenedFY20252023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Trends in performance and profitability, including growth and changes in revenue and profitA theme 623 companies write about · 47 as a headwind · 766 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 126 companies compared. The sentences above are computed from all 126.Comparing 200 of the theme's 902 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「このような状況下においても、当社グループの事業は重点品目の伸長等により増収増益となり、「中期経営計画2025」で目標として掲げた売上高700億円、営業利益率8%、ROE8%を達成いたしました。」

    2025年度は重点品目の伸長等により売上高71,127百万円、営業利益率約8.2%、ROE8.0%となり、従来中期計画の主要目標を達成したと記載している。
  2. 2026-05-11AdvancedEarnings

    「The Group’s businesses achieved higher revenue and profit due to growth in key products and other factors, and achieved the targets set under the Medium-Term Management Plan 2025 of revenue of ¥70.0 billion, an operating margin of 8% and ROE of 8%.」

    The company reported that both revenue and operating profit increased in the fiscal year ended March 2026, following the decline in operating profit in the previous year.
  3. FY2025WorsenedAnnual report

    「当連結会計年度の当社グループの売上高は前年同期から1,296百万円増加し、64,139百万円(前期比2.1%増)となりました。…営業利益は前年同期から1,168百万円減の5,331百万円(前期比18.0%減)となりました。」

    2024年度は増収となった一方、研究開発の進展に伴う費用増等により営業利益は18.0%減少し、営業利益率も前年度の10.3%から約8.3%へ低下した。
  4. FY2024AdvancedAnnual report

    「当連結会計年度の当社グループの売上高は前年同期から2,381百万円増加し、62,843百万円となりました。…営業利益は前年同期から1,392百万円増の6,500百万円、売上高営業利益率は10.3%となりました。」

    2023年度は売上高62,843百万円、営業利益6,500百万円、営業利益率10.3%となり、前年度から増収・営業利益増となった。
  5. FY2023First statedAnnual report

    「売上高は前年同期から3,853百万円増加し、60,461百万円となりました。…営業利益は前年同期から312百万円増の5,108百万円、売上高営業利益率は8.4%となりました。」

    2022年度は売上高60,461百万円、営業利益5,108百万円、売上高営業利益率8.4%となり、売上高・営業利益とも前年度を上回った。
Moved together

"Revenue and Profit Growth in the Pharmaceuticals Business" moved the same way as this thread, in the same document, in 4 of its 5 moves.

433222★123456
  1. ★This thread
  2. 1Revenue and Profit Growth in the Pharmaceuticals Business4×
  3. 2FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company3×
  4. 3Launch of the Dysmenorrhea Treatment DroEthi3×
  5. 4Overseas Business Expansion Focused on Asia2×
  6. 5Establishment of an ESG Committee and Identification of 17 Material Issues2×
  7. 6Developing and Utilizing Human Resources Through a New Personnel System and Planned Training2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings of 2026-05-11: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.